Women over 50 lost 35% more weight with this surprising combo
Why it matters: This combo could revolutionize weight management for postmenopausal women, improving health outcomes.
- Mayo Clinic research, published in The Lancet Obstetrics, Gynaecology, & Women's Health, highlights a significant weight loss advantage for postmenopausal women combining MHT with tirzepatide.
- Women over 50 on this combined therapy lost approximately 35% more weight, hinting at a novel strategy to combat increased weight gain and associated health risks like cardiovascular disease and type 2 diabetes post-menopause.
- Hormone therapy, already the most effective treatment for menopausal symptoms, may also enhance the efficacy of cutting-edge weight-loss medications like tirzepatide, though further randomized trials are needed to confirm causality.
A groundbreaking Mayo Clinic study reveals that postmenopausal women using menopausal hormone therapy (MHT) alongside the obesity drug tirzepatide achieved 35% greater weight loss than those on tirzepatide alone. This surprising synergy suggests a powerful new approach to managing weight and cardiometabolic risks in women after menopause, potentially leading to more personalized and effective treatments.
